Jasper Therapeutics (JSPR) Operating Income (2020 - 2025)
Jasper Therapeutics (JSPR) posted quarterly Operating Income of -$15.8 million for Q4 2025, up 37.36% year-over-year from -$11.5 million in Q4 2024, and up 17.36% quarter-over-quarter from -$19.2 million in Q3 2025.
Jasper Therapeutics (JSPR) Operating Income (2020 - 2025) Analysis & Trends
Jasper Therapeutics' Operating Income history runs 6 years deep, the most recent figure standing at -$15.8 million for Q4 2025.
- In Q4 2025, Operating Income rose 37.36% year-over-year to -$15.8 million; the TTM figure through Dec 2025 stood at -$83.9 million (down 10.03% YoY), while the FY2025 annual figure was -$83.9 million, down 10.03% from the prior year.
- Operating Income for Q4 2025 stood at -$15.8 million, up from -$19.2 million in the prior quarter.
- The five-year high for Operating Income was -$6.3 million in Q1 2021, with the low at -$27.1 million in Q2 2025.
- The 5-year median for Operating Income is -$15.5 million (2024), against an average of -$15.9 million.
- The sharpest annual moves came in 2021 and 2025: Operating Income tumbled 2634.99% in 2021, then jumped 37.36% in 2025.
- Jasper Therapeutics' Operating Income stood at -$12.1 million in 2021, then decreased by 13.78% to -$13.7 million in 2022, then dropped by 28.94% to -$17.7 million in 2023, then tumbled by 42.65% to -$25.3 million in 2024, then jumped by 37.36% to -$15.8 million in 2025.
- Business Quant data shows JSPR's Operating Income at -$15.8 million in Q4 2025, -$19.2 million in Q3 2025, and -$27.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Jasper Therapeutics | 20.06 Mn | 20.06 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -15.84 Mn |
| Sep 30, 2025 | -19.17 Mn |
| Jun 30, 2025 | -27.08 Mn |
| Mar 31, 2025 | -21.80 Mn |
| Dec 31, 2024 | -25.29 Mn |
| Sep 30, 2024 | -19.89 Mn |
| Jun 30, 2024 | -15.99 Mn |
| Mar 31, 2024 | -15.07 Mn |
| Dec 31, 2023 | -17.73 Mn |
| Sep 30, 2023 | -19.36 Mn |
| Jun 30, 2023 | -17.83 Mn |
| Mar 31, 2023 | -13.95 Mn |
| Dec 31, 2022 | -13.75 Mn |
| Sep 30, 2022 | -12.71 Mn |
| Jun 30, 2022 | -11.96 Mn |
| Mar 31, 2022 | -12.78 Mn |
| Dec 31, 2021 | -12.08 Mn |
| Sep 30, 2021 | -10.08 Mn |
| Jun 30, 2021 | -8.42 Mn |
| Mar 31, 2021 | -6.25 Mn |